title: CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals.
abstract: BACKGROUND
  Whether vexing clinical decision-making dilemmas can be partly addressed by recent advances in genomics is unclear. For example, when to initiate highly active antiretroviral therapy (HAART) during HIV-1 infection remains a clinical dilemma. This decision relies heavily on assessing AIDS risk based on the CD4+ T cell count and plasma viral load. However, the trajectories of these two laboratory markers are influenced, in part, by polymorphisms in CCR5, the major HIV coreceptor, and the gene copy number of CCL3L1, a potent CCR5 ligand and HIV-suppressive chemokine. Therefore, we determined whether accounting for both genetic and laboratory markers provided an improved means of assessing AIDS risk.
  
  
  RESULTS
  In a prospective, single-site, ethnically-mixed cohort of 1,132 HIV-positive subjects, we determined the AIDS risk conveyed by the laboratory and genetic markers separately and in combination. Subjects were assigned to a low, moderate or high genetic risk group (GRG) based on variations in CCL3L1 and CCR5. The predictive value of the CCL3L1-CCR5 GRGs, as estimated by likelihood ratios, was equivalent to that of the laboratory markers. GRG status also predicted AIDS development when the laboratory markers conveyed a contrary risk. Additionally, in two separate and large groups of HIV+ subjects from a natural history cohort, the results from additive risk-scoring systems and classification and regression tree (CART) analysis revealed that the laboratory and CCL3L1-CCR5 genetic markers together provided more prognostic information than either marker alone. Furthermore, GRGs independently predicted the time interval from seroconversion to CD4+ cell count thresholds used to guide HAART initiation.
  
  
  CONCLUSIONS
  The combination of the laboratory and genetic markers captures a broader spectrum of AIDS risk than either marker alone. By tracking a unique aspect of AIDS risk distinct from that captured by the laboratory parameters, CCL3L1-CCR5 genotypes may have utility in HIV clinical management. These findings illustrate how genomic information might be applied to achieve practical benefits of personalized medicine.
authors.affiliation: Veterans Administration Research Center for AIDS and HIV-1 Infection, South Texas Veterans Health Care System, San Antonio, Texas, United States of America.
authors.forename: Hemant
authors.initials: H
authors.lastname: Kulkarni
authors.forename: Brian K
authors.initials: BK
authors.lastname: Agan
authors.forename: Vincent C
authors.initials: VC
authors.lastname: Marconi
authors.forename: Robert J
authors.initials: RJ
authors.lastname: O'Connell
authors.forename: Jose F
authors.initials: JF
authors.lastname: Camargo
authors.forename: Weijing
authors.initials: W
authors.lastname: He
authors.forename: Judith
authors.initials: J
authors.lastname: Delmar
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Phelps
authors.forename: George
authors.initials: G
authors.lastname: Crawford
authors.forename: Robert A
authors.initials: RA
authors.lastname: Clark
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Dolan
authors.forename: Sunil K
authors.initials: SK
authors.lastname: Ahuja
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000235:genetics*; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D019742:Chemokines, CC / Q000235:genetics*; D015331:Cohort Studies; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000175:diagnosis / Q000235:genetics*; D015497:HIV-1 / Q000378:metabolism*; D006801:Humans; D016013:Likelihood Functions; D008297:Male; D011446:Prospective Studies; D019713:Receptors, CCR5 / Q000235:genetics*; D012306:Risk
chemical_list: C492767:CCL3L1 protein, human; D019742:Chemokines, CC; D019713:Receptors, CCR5
references.citation: Nat Genet. 2004 Jun;36(6):565-74
references.pmid: 15167933
references.citation: Lancet. 1998 Sep 12;352(9131):866-70
references.pmid: 9742978
references.citation: J Immunol. 2000 Oct 15;165(8):4388-96
references.pmid: 11035076
references.citation: Stat Med. 2004 Jan 30;23(2):271-83
references.pmid: 14716728
references.citation: Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15590-5
references.pmid: 12434015
references.citation: Curr Opin HIV AIDS. 2008 May;3(3):342-8
references.pmid: 19372988
references.citation: JAMA. 2006 Aug 16;296(7):815-26
references.pmid: 16905787
references.citation: J Infect Dis. 1994 Apr;169(4):893-7
references.pmid: 7907646
references.citation: AIDS. 2001 Sep 7;15(13):1627-34
references.pmid: 11546936
references.citation: JAMA. 1999 Aug 25;282(8):734
references.pmid: 10463706
references.citation: J Infect Dis. 1998 Oct;178(4):1024-9
references.pmid: 9806030
references.citation: Nat Immunol. 2001 Feb;2(2):102-7
references.pmid: 11175801
references.citation: Nat Immunol. 2007 Dec;8(12):1324-36
references.pmid: 17952079
references.citation: Eur J Immunol. 2002 Oct;32(10):3016-26
references.pmid: 12355456
references.citation: Ann Emerg Med. 1998 Mar;31(3):391-7
references.pmid: 9506499
references.citation: Eur J Emerg Med. 2002 Jun;9(2):115-21
references.pmid: 12131632
references.citation: Clin Infect Dis. 2005 Aug 1;41(3):361-72
references.pmid: 16007534
references.citation: Clin Immunol. 2003 Sep;108(3):234-40
references.pmid: 14499246
references.citation: Ann Intern Med. 1997 Jun 15;126(12):946-54
references.pmid: 9182471
references.citation: Curr Opin HIV AIDS. 2008 Jan;3(1):28-35
references.pmid: 19372941
references.citation: HIV Med. 2003 Jul;4(3):255-62
references.pmid: 12859325
references.citation: J Immunol. 1997 May 1;158(9):4129-36
references.pmid: 9126972
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5199-204
references.pmid: 11320252
references.citation: Clin Infect Dis. 2007 Feb 1;44(3):441-6
references.pmid: 17205456
references.citation: MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55
references.pmid: 12027060
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15006-10
references.pmid: 14657379
references.citation: Annu Rev Med. 2003;54:535-51
references.pmid: 12525683
references.citation: Nat Med. 2005 Nov;11(11):1180-7
references.pmid: 16208318
references.citation: Blood. 2003 Feb 1;101(3):807-14
references.pmid: 12393512
references.citation: J Virol. 2005 May;79(9):5625-31
references.pmid: 15827177
references.citation: Annu Rev Immunol. 2004;22:891-928
references.pmid: 15032599
references.citation: J Infect Dis. 2001 Jun 1;183(11):1574-85
references.pmid: 11335892
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13795-800
references.pmid: 12374865
references.citation: Clin Infect Dis. 2004 Dec 1;39(11):1699-704
references.pmid: 15578373
references.citation: Science. 2005 Mar 4;307(5714):1434-40
references.pmid: 15637236
references.citation: Immunogenetics. 2007 Oct;59(10):793-8
references.pmid: 17874089
references.citation: JAMA. 2006 Sep 27;296(12):1498-506
references.pmid: 17003398
references.citation: AIDS. 2000 May 5;14(7):821-6
references.pmid: 10839590
references.citation: Science. 1996 Sep 27;273(5283):1856-62
references.pmid: 8791590
references.citation: AIDS. 2006 Sep 11;20(14):1879-83
references.pmid: 16954729
references.citation: Eur J Immunol. 2000 Jul;30(7):2048-55
references.pmid: 10940894
references.citation: Immunity. 2007 Sep;27(3):406-16
references.pmid: 17892849
references.citation: Mol Med. 1997 Jan;3(1):23-36
references.pmid: 9132277
references.citation: Nat Immunol. 2006 Oct;7(10):1101-8
references.pmid: 16964261
references.citation: Adv Genet. 2001;42:273-86
references.pmid: 11037327
references.citation: Science. 2007 Apr 13;316(5822):222-34
references.pmid: 17431167
references.citation: Ann Intern Med. 2000 Sep 19;133(6):401-10
references.pmid: 10975957
references.citation: J Infect Dis. 2006 Sep 1;194(5):633-41
references.pmid: 16897662
references.citation: J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):168-75
references.pmid: 11404539
references.citation: J Infect Dis. 2008 Mar 1;197(5):721-7
references.pmid: 18266604
references.citation: Nature. 2006 Apr 13;440(7086):890-5
references.pmid: 16612374
references.citation: Virology. 2007 Aug 1;364(2):281-90
references.pmid: 17428518
references.citation: J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):114-6
references.pmid: 14501804
references.citation: J Infect Dis. 2002 Apr 15;185(8):1055-61
references.pmid: 11930315
references.citation: Ann Behav Med. 2003 Dec;26(3):172-81
references.pmid: 14644693
references.citation: JAMA. 2004 Jul 14;292(2):251-65
references.pmid: 15249575
references.citation: Nat Med. 2008 Apr;14(4):413-20
references.pmid: 18376407
references.citation: J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):245-54
references.pmid: 18360285
references.citation: Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12004-9
references.pmid: 10518566
references.citation: Virology. 2004 Mar 1;320(1):75-84
references.pmid: 15003864
references.citation: J Clin Invest. 1999 Aug;104(4):R1-5
references.pmid: 10449444
references.citation: Annu Rev Immunol. 2003;21:265-304
references.pmid: 12524385
references.citation: J Infect Dis. 2005 Feb 1;191 Suppl 1:S68-77
references.pmid: 15630678
references.citation: J Virol. 2005 Sep;79(18):11677-84
references.pmid: 16140745
references.citation: AIDS. 1998 Oct 1;12(14):1823-32
references.pmid: 9792383
references.citation: AIDS. 2006 Jul 13;20(11):1531-8
references.pmid: 16847408
references.citation: J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):263-71
references.pmid: 18391751
references.citation: J Immunol. 1996 Mar 15;156(6):2095-2103
references.pmid: 8690897
references.citation: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):377-8
references.pmid: 17079996
references.citation: AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1123-33
references.pmid: 10954887
references.citation: J Infect Dis. 2000 Mar;181(3):927-32
references.pmid: 10720514
references.citation: Nat Immunol. 2005 May;6(5):465-71
references.pmid: 15821738
references.citation: J Virol. 2000 Mar;74(6):2584-93
references.pmid: 10684272
references.citation: Clin Infect Dis. 2004 Dec 1;39(11):1705-8
references.pmid: 15578374
references.citation: AIDS. 2002 Sep 27;16(14):1859-66
references.pmid: 12351945
references.citation: AIDS. 2003 Sep 5;17(13):1907-15
references.pmid: 12960823
references.citation: J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):192-9
references.pmid: 9949307
references.citation: AIDS. 2007 Aug 20;21(13):1753-61
references.pmid: 17690574
references.citation: Clin Breast Cancer. 2003 Aug;4(3):203-9
references.pmid: 14499014
references.citation: J Acquir Immune Defic Syndr (1988). 1993 Nov;6(11):1248-57
references.pmid: 7901383
references.citation: J Biol Chem. 2000 Jun 23;275(25):18946-61
references.pmid: 10747879
references.citation: J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):288-93
references.pmid: 16249702
references.citation: J Gen Virol. 2006 Jul;87(Pt 7):2055-2065
references.pmid: 16760409
references.citation: Science. 1998 Dec 4;282(5395):1907-11
references.pmid: 9836644
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8401-6
references.pmid: 12815099
references.citation: FEBS Lett. 1999 Aug 27;457(2):219-22
references.pmid: 10471782
references.citation: Ann Allergy. 1984 Feb;52(2):75-82
references.pmid: 6696298
references.citation: J Infect Dis. 1995 Jul;172(1):79-87
references.pmid: 7797948